摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

methyl 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynyltriazole-4-carboxylate | 1402406-22-7

中文名称
——
中文别名
——
英文名称
methyl 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynyltriazole-4-carboxylate
英文别名
——
methyl 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynyltriazole-4-carboxylate化学式
CAS
1402406-22-7
化学式
C11H13N3O6
mdl
——
分子量
283.241
InChiKey
MHWIGVGCXYOTPL-PEBGCTIMSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.5
  • 重原子数:
    20
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    127
  • 氢给体数:
    3
  • 氢受体数:
    8

反应信息

  • 作为产物:
    描述:
    甲醇 、 ethyl 1-[(2R,3R,4R,5R)-3,4-diacetyloxy-5-(acetyloxymethyl)oxolan-2-yl]-5-(2-trimethylsilylethynyl)triazole-4-carboxylate 在 作用下, 生成 1-(4-carbamoyl-5-ethynyl-[1,2,3]triazol-1-yl)-β-D-ribofuranosemethyl 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-ethynyltriazole-4-carboxylate
    参考文献:
    名称:
    ACADESINE DERIVATIVES, PRODUCTS AND COMPOSITIONS INCLUDING SAME, THERAPUETIC USES THEREOF, AND METHODS FOR SYNTHESIZING SAME
    摘要:
    本文描述了作为药物的Acadesine衍生物,以及用于治疗癌症,特别是慢性髓细胞白血病的衍生物。此外,还描述了包含衍生物和至少一种第二活性成分的产品,作为联合产品进行同时、分离或顺序给药,用于治疗癌症,以及含有衍生物和药用可接受载体的制药组合物。最后,描述了抑制体外细胞增殖的方法,包括将体外细胞与衍生物接触,以及合成所述衍生物的方法。
    公开号:
    US20140179626A1
点击查看最新优质反应信息

文献信息

  • DÉRIVÉS DE L'ACADÉSINE, PRODUITS ET COMPOSITIONS LES COMPRENANT, LEURS UTILISATIONS THÉRAPEUTIQUES ET LEURS PROCÉDÉS DE SYNTHÈSE
    申请人:Université Nice Sophia Antipolis
    公开号:EP2699240B1
    公开(公告)日:2015-05-27
  • US9173892B2
    申请人:——
    公开号:US9173892B2
    公开(公告)日:2015-11-03
  • ACADESINE DERIVATIVES, PRODUCTS AND COMPOSITIONS INCLUDING SAME, THERAPUETIC USES THEREOF, AND METHODS FOR SYNTHESIZING SAME
    申请人:Benhida Rachid
    公开号:US20140179626A1
    公开(公告)日:2014-06-26
    Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described. Finally, a method for inhibiting the in vitro cell proliferation including the placement of an in vitro cell in contact with the derivatives and methods for synthesis of said derivatives and methods for synthesis of the derivatives are described.
    本文描述了作为药物的Acadesine衍生物,以及用于治疗癌症,特别是慢性髓细胞白血病的衍生物。此外,还描述了包含衍生物和至少一种第二活性成分的产品,作为联合产品进行同时、分离或顺序给药,用于治疗癌症,以及含有衍生物和药用可接受载体的制药组合物。最后,描述了抑制体外细胞增殖的方法,包括将体外细胞与衍生物接触,以及合成所述衍生物的方法。
查看更多

同类化合物

利巴韦林杂质G 利巴韦林杂质E 利巴韦林杂质B 利巴韦林 利巴韦林 三氮唑核苷脒盐酸盐 三氮唑核苷羧酸 三氮唑核苷5'-氨基磺酸 三氮唑核苷-5'-磷酸酯 三氮唑核苷 5'-二磷酸酯 三氮唑核苷 5'-三磷酸酯 三氮唑核苷 2',3',5'-三乙酸酯 三乙酰利巴韦林甲酯 [5-(3-氨基-1,2,4-三唑-1-基)-3,4-二苯甲酰氧基-四氢呋喃-2-基]甲基苯甲酸酯 [(2R,3S,4R,5R)-5-(3-硫代氨基甲酰-1,2,4-三唑-1-基)-3,4-二羟基四氢呋喃-2-基]甲基氨基磺酸 [(2R,3S,4R,5R)-5-(3-氨基羰基-1,2,4-三唑-1-基)-3,4-二羟基-四氢呋喃-2-基]甲基二氢磷酸酯与N,N-二乙基乙胺的化合物 5-氨基-1-[(2R,3R,4S,5R)-3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]-1,2,4-三唑-3-甲脒盐酸盐 5'-O-吡喃葡萄糖基三氮唑核苷 5'-O-吡喃半乳糖基三氮唑核苷 3-氰基-1-(2,3,5-三-O-乙酰基-beta-D-呋喃核糖基)-1,2,4-三唑 2’,3’-异亚丙基三氮唑核苷 2',3'-异亚丙基α-利巴韦林 2'-脱氧三氮唑核苷 1-Β-D-呋喃核糖基-1H-1,2,4-三氮唑-3-羧酸甲酯 1-[2,3-O-异亚丙基-beta-D-呋喃核糖基]-1,2,4-三唑-3-羧酸甲酯 1-[(2S,3S,4S,5S)-3,4-二羟基-5-(羟基甲基)四氢呋喃-2-基]-1,2,4-三唑-3-甲酰胺 1-[(2R,3R,4R,5R)-3,4-二丁氧基-5-(丁氧基甲基)四氢呋喃-2-基]-1,2,4-三唑-3-甲酰胺 1-(2-C-甲基-BETA-D-呋喃核糖基)-1H-1,2,4-三唑-3-甲酰胺 (2R,3S,4R,5R)-2-(羟基甲基)-5-[3-(甲氧基亚胺甲酰基)-1,2,4-三唑-1-基]四氢呋喃-3,4-二醇 (2R,3R,4S,5R)-2-[3-(乙氧基亚胺甲酰基)-1,2,4-三唑-1-基]-5-(羟基甲基)四氢呋喃-3,4-二醇 N1-(2,3,5-tri-O-benzoyl-β-D-ribofuranosyl)-C4-(coumarin-7-oxymethyl)-1,2,3-triazole 4,5-dibromo-1-(5-O-sulfamoyl-β-D-ribofuranosyl)triazole (2R,3R,4S,5R)-3'-(2-fluorophenyl)-5-(hydroxymethyl)-4,5-dihydro-3H,4'H,6'H-spiro[furan-2,7'-[1,2,3]triazolo[5,1-c][1,4]oxazine]-3,4-diol 4-((1-(β-D-ribofuranos-1-yl)-1,2,3-triazol-4-yl)methoxy)-2-phenylquinazoline ribavirin-5’-O-bis(benzoxy-L-alaninyl)phoshate 1-(5-deoxy-5-N-phosphonomethylamino-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide (2R,3R,4S,5R)-3'-(4-chlorophenyl)-5-(hydroxymethyl)-4,5-dihydro-3H,4'H,6'H-spiro[furan-2,7'-[1,2,3]triazolo[5,1-c][1,4]oxazine]-3,4-diol 1-(4'-azido-2'-deoxy-2'-fluoro-β-D-arabinofuranosyl)-4-cyclopropyl-[1,2,3]-triazole 1-(5-O-thiophosphoryl-β-D-ribofuranosyl)-1,2,4-triazole-3-carboxamide 5-[2-(4-chlorophenyl)ethynyl]-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[2-(1-methylimidazol-4-yl)ethynyl]-1,2,4-triazole-3-carboxamide 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[2-[2-(trifluoromethyl)phenyl]ethynyl]-1,2,4-triazole-3-carboxamide 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-[2-(4-methylphenyl)ethynyl]-1,2,4-triazole-3-carboxamide 5-(4-trifluoromethylphenylethynyl)-1-(2,3,5-tri-hydroxy-β-D-ribofuranosyl)-1H-[1,2,4]triazole-3-carboxylic acid amide 1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(2-phenylethynyl)-1,2,4-triazole-3-carboxamide 5-(5-chloropent-1-ynyl)-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide 5-(3-trifluoromethyl-phenylethynyl)-1-(2,3,5-tri-hydroxy-β-D-ribofuranosyl)-1H-[1,2,4]triazole-3-carboxylic acid amide 5-(thiophen-3-ylethynyl)-1-(2,3,5-tri-hydroxy-β-D-ribofuranosyl)-1H-[1,2,4]triazole-3-carboxylic acid amide 5-(4-methoxyphenylethynyl)-1-(2,3,5-tri-hydroxy-β-D-ribofuranosyl)-1H-[1,2,4]triazole-3-carboxylic acid amide 4-tetradecyloxymethyl-1-(β-D-arabinofuranosyl)-1,2,3-triazole